Acquisitions (Tables)

12 Months Ended

Sep. 30, 2011

Acquisitions [Abstract]

Fair values of assets and liabilities assumed in Carmel Pharma acquisition

Product rights	$	161,800
Customer relationships		4,100
Deferred tax assets		2,135
Other		32,001
Total identifiable assets acquired		200,036
Deferred tax liabilities		(45,035	)
Other		(13,276	)
Total liabilities assumed		(58,311	)
Net identifiable assets acquired		141,725
Goodwill		145,386
Net assets acquired	$	287,111

Developed technology	$	111,500
Acquired in-process research and development		42,300
Other intangibles		2,850
Deferred tax assets		10,442
Other		8,176
Total identifiable assets acquired		175,268
Deferred tax liabilities		(59,869	)
Other		(4,728	)
Total liabilities assumed		(64,597	)
Net identifiable assets acquired		110,671
Goodwill		94,299
Net assets acquired	$	204,970

Acquired in-process research and development	$	169,000
Deferred tax assets		23,000
Other		8,843
Total identifiable assets acquired		200,843
Deferred tax liabilities		(64,221	)
Other		(6,468	)
Total liabilities assumed		(70,689	)
Net identifiable assets acquired		130,154
Goodwill		147,456
Net assets acquired	$	277,610

Fair value of consideration transferred

Cash	$	274,756
Settlement of preexisting relationship		2,854	(A)
Total	$	277,610

(A) The acquisition effectively settled a prepaid asset associated with a pre-existing relationship with HandyLab, as discussed in further detail below.